Centessa Pharmaceuticals Stock Forecast, Price & News

-0.15 (-0.60 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume73,551 shs
Average Volume278,850 shs
Market Capitalization$2.23 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.00 out of 5 stars

Medical Sector

2081st out of 2,105 stocks

Pharmaceutical Preparations Industry

825th out of 832 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Centessa Pharmaceuticals (NASDAQ:CNTA) Frequently Asked Questions

What stocks does MarketBeat like better than Centessa Pharmaceuticals?

Wall Street analysts have given Centessa Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Centessa Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Centessa Pharmaceuticals' key executives?

Centessa Pharmaceuticals' management team includes the following people:
  • Dr. Jamie Coleman Ph.D., Chief Operating Officer of LockBody
  • Mr. Trevor Baglin Ph.D., Co-Founder & Chief Medical Officer of Z Factor
  • Mr. James Huntington, Co-Founder & CEO of Apcintex
  • Prof. Nicholas Morrell, Co-founder & CEO of Morphogen-IX
  • Mr. Jonathan Finlay, Chief Exec. Officer of LockBody
  • Dr. Saurabh Saha, CEO & Director (Age 44)
  • Dr. Gregory M. Weinhoff M.B.A., M.D., MBA, Chief Financial Officer (Age 50)
  • Ms. Marella Thorell, Chief Accounting Officer (Age 54)
  • Dr. David M. Chao, Chief Admin. Officer (Age 53)
  • Mr. Iqbal J. Hussain, Gen. Counsel (Age 40)

Who are some of Centessa Pharmaceuticals' key competitors?

When did Centessa Pharmaceuticals IPO?

(CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

What is Centessa Pharmaceuticals' stock symbol?

Centessa Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNTA."

When does Centessa Pharmaceuticals' quiet period expire?

Centessa Pharmaceuticals' quiet period expires on Wednesday, July 7th. Centessa Pharmaceuticals had issued 16,500,000 shares in its initial public offering on May 28th. The total size of the offering was $330,000,000 based on an initial share price of $20.00. During Centessa Pharmaceuticals' quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Centessa Pharmaceuticals?

Shares of CNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Centessa Pharmaceuticals' stock price today?

One share of CNTA stock can currently be purchased for approximately $24.76.

How much money does Centessa Pharmaceuticals make?

Centessa Pharmaceuticals has a market capitalization of $2.23 billion.

What is Centessa Pharmaceuticals' official website?

The official website for Centessa Pharmaceuticals is

Where are Centessa Pharmaceuticals' headquarters?


How can I contact Centessa Pharmaceuticals?

Centessa Pharmaceuticals' mailing address is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. The company can be reached via phone at 44-73-9178-9784 or via email at [email protected]

This page was last updated on 6/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.